SCHEMBL11297865

SCHEMBL11297865

CCNc1ncc2c(n1)-c1cc(C)sc1CC2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 5/20 0.36
CDK2 P24941 10/20 0.36
CCNT1 O60563 7/20 0.36
CDK1 P06493 7/20 0.36
CDK4 P11802 7/20 0.36
CCNB1 P14635 7/20 0.36
CCND1 P24385 7/20 0.36
CCNE1 P24864 7/20 0.36
CDK9 P50750 7/20 0.36
CDK7 P50613 6/20 0.36
CCNH P51946 6/20 0.36
MEN1 O00255 3/20 0.35
ALDH1A1 P00352 3/20 0.35
KMT2A Q03164 3/20 0.35
KDM4E B2RXH2 2/20 0.35
GAA P10253 2/20 0.35
MAPT P10636 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
LMNA P02545 1/20 0.35
CCNA2 P20248 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13373313 0.86 IKBKB (0.35) IKBKBCDK2CCNT1CDK1CDK4
SCHEMBL11292385 0.85 IKBKB (0.38) IKBKBCDK2CCNT1CDK1CDK4
SCHEMBL11300059 0.84 IKBKB (0.36) IKBKBCDK2CCNT1CDK1CDK4
SCHEMBL13373281 0.79 IKBKB (0.56) IKBKBCDK2CDK9CDK7MEN1
SCHEMBL13373279 0.79 CDK2 (0.42) IKBKBCDK2CCNT1CDK1CDK4
SCHEMBL11299092 0.79 ALDH1A1 (0.32) MEN1ALDH1A1KMT2ACYP1A2CYP2C19
SCHEMBL13592001 0.78 CDK2 (0.46) CDK2CCNE1CCNA2CCNA1
SCHEMBL13373284 0.78 ADORA2A (0.32) CDK2CCNE1MEN1ALDH1A1KMT2A
SCHEMBL11298835 0.76 CDK2 (0.37) IKBKBCDK2CCNT1CDK1CDK4
SCHEMBL13373302 0.75 CDK2 (0.34) IKBKBCDK2CCNT1CDK1CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288400-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-16 US disclosed
US-20120183577-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120183577-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K6 IKBKB 540/4885CDK2 65/4885CCNT1 957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.